Market Herald logo


Be the first with the news that moves the market
  • Invex Therapeutics has received a Japanese patent for its brain injury treatment
  • It specialises in treating people who have conditions caused by increasing pressure in the brain
  • For the treatment, Invex is repurposing a drug first designed to help people with type 2 diabetes
  • The company is looking to gain more patents globally
  • Invex’s share price is up nearly five per cent today, currently sitting at 65 cents per share

Biopharmaceutical company Invex Therapeutics, has received a Japanese patent for its treatment of neurological disorders.

The patented treatment is predominately used to heal intracranial pressure, which is when pressure increases in your brain.

The company’s focus in on repurposing the approved drug Exenatide to treat neurological conditions. Exenatide first gained approval in 2005 as a means to treat type 2 diabetes.

Invex advised its treatment is being observed in people with a range of neurological conditions effected by increasing pressure in the brain.

These include: idiopathic intracranial hypertension, secondary pseudotumour cerebri, hydrocephalus, normal pressure hydrocephalus, meningitis, brain trauma, brain injury and venous sinus thrombosis.

“This is a significant first step in securing world-wide protection for Invex’s drug candidates,” Chairman Dr Jason Loveridge said on the patent.

“We will continue to work with the patent offices of other jurisdictions to secure similar protection in other territories,” Dr Jason continued.

Invex listed on the Australian Securities Exchange this year, raising $12 million during its initial public offering.

Invex’s share price is up 4.84 per cent today, currently sitting at 65 cents apiece, as of 10:45 am AEST.

IXC by the numbers
More From The Market Herald
Heramed (ASX:HMD) - CEO and Co Founder, David Groberman

" HeraMED (ASX:HMD) raises $2.39m via convertible note placement

HeraMED (HMD) has raised roughly $2.39 million through a convertible note placement.
NeuroScientific Biopharmaceuticals (ASX:NSB) - MD and CEO, Matthew Liddelow

" NeuroScientific Biopharmaceuticals (ASX:NSB) completes safety pharmacology studies

NeuroScientific Biopharmaceuticals (NSB) has seen no adverse events during its non-clinical studies of EmtinB.
PharmAust (ASX:PAA) - Chief Scientific Officer, Dr Richard Mollard

" PharmAust (ASX:PAA) identifies optimal MPL dose for canine cancer

Clinical-stage biotech company PharmAust (PAA) has identified the optimum monepantel (MPL) drug plasma range for dogs with B-cell lymphoma.
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion Group (ASX:ALC) extends contract with Sydney Local Health District

Alcidion Group (ALC) has expanded the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD).